Results 111 to 120 of about 24,911 (203)

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

Journal of Blood Medicine, 2015
Christopher Arthur,1 Jaroslav Cermak,2 Jacques Delaunay,3 Jirí Mayer,4 Grzegorz Mazur,5 Xavier Thomas,6 Agnieszka Wierzbowska,7 Mark M Jones,8 Erhan Berrak,8 Hagop Kantarjian9 1Department of Haematology, Royal North Shore Hospital, Sydney, NSW ...
Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H   +9 more
doaj  

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen [PDF]

, 2017
Abboud, Camille N, Ali, Alaa M, Cashen, Amanda F, DiPersio, John F, Fehniger, Todd A, Gao, Feng, Ghobadi, Armin, Jacoby, Meagan A, Oh, Stephen T, Pusic, Iskra, Romee, Rizwan, Schroeder, Mark A, Stockerl-Goldstein, Keith E, Uy, Geoffrey L, Vij, Ravi, Wartman, Lukas D, Weisel, Daniel, Welch, John S, Westervelt, Peter   +18 more
core   +2 more sources

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. [PDF]

Blood Adv
Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton N, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC.   +13 more
europepmc   +1 more source

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. [PDF]

Cancer Res Commun
Anabtawi N, Drabison T, Ham AF, Boeckman M, Stromatt JC, Orwick SJ, Buelow DR, Kaur T, Ahmed EA, Eisenmann ED, Govindarajan R, Sparreboom A, Baker SD.   +12 more
europepmc   +1 more source

Serial Determinations of Molecular Aberrations in Patients with Acute Myeloid Leukemia During Treatment with Oral Decitabine/Cedazuridine. [PDF]

Cancers (Basel)
Geissler K, Benetka G, Prinz-Wohlgenannt M, Sperr WR.   +3 more
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

DNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells. [PDF]

Exp Mol Med
Pu Y, Wang Z, Tao S, Yang EJ, Zhang J, Han Y, Wu S, Ren G, Chen LJ, Zhang X, Tan K, Li G, Miao K, Wang J, Dang Y, Shim JS.   +15 more
europepmc   +1 more source

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +1 more source

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome. [PDF]

Ann Hematol
Gao Z, Yang F, Pan H, Zhang L, Li W, Li R, Zhao J, Luo Y, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Ge M, Zheng Y, Fang L, Shi J.   +17 more
europepmc   +1 more source

Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms. [PDF]

Cancer Pathog Ther
Zhang Z, Wang Y, Zhang H, Zhao J, Yang Z, Wang X, Tang Y, Lu X, Xu R.   +8 more
europepmc   +1 more source